Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response

Cancer Letters

Volumn 328, Issue 1, 2013, Pages 1-9

  Pondugula, Satyanarayana R ^a   Mani, Sridhar ^b  

^a AUBURN UNIVERSITY   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; Dog; Drug resistance; Endocrine disruption; PXR

Indexed keywords

EID: 84868497825     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.08.030     Document Type: Review

References (154)

1. Kliewer S.A., Moore J.T., Wade L., Staudinger J.L., Watson M.A., Jones S.A., McKee D.D., Oliver B.B., Willson T.M., Zetterstrom R.H., Perlmann T., Lehmann J.M. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998, 92:73-82.
2. Lehmann J.M., McKee D.D., Watson M.A., Willson T.M., Moore J.T., Kliewer S.A. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 1998, 102:1016-1023.
3. Desai P.B., Nallani S.C., Sane R.S., Moore L.B., Goodwin B.J., Buckley D.J., Buckley A.R. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab. Dispos. 2002, 30:608-612.
4. Mani S., Huang H., Sundarababu S., Liu W., Kalpana G., Smith A.B., Horwitz S.B. Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents. Clin. Cancer Res. 2005, 11:6359-6369.
5. Synold T.W., Dussault I., Forman B.M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med. 2001, 7:584-590.
6. Barrett J.R. BPA and PXR activation: human receptor is affected, mouse receptor is not. Environ. Health Perspect. 2012, 120:A122.
7. Sui Y., Ai N., Park S.H., Rios-Pilier J., Perkins J.T., Welsh W.J., Zhou C. Bisphenol A and its analogues activate human pregnane X receptor. Environ. Health Perspect. 2012, 120:399-405.
8. Ding X., Staudinger J.L. Induction of drug metabolism by forskolin: the role of the pregnane X receptor and the protein kinase a signal transduction pathway. J. Pharmacol. Exp. Ther. 2005, 312:849-856.
9. Ding X., Staudinger J.L. Repression of PXR-mediated induction of hepatic CYP3A gene expression by protein kinase C. Biochem. Pharmacol. 2005, 69:867-873.
10. Johnson D.R., Li C.W., Chen L.Y., Ghosh J.C., Chen J.D. Regulation and binding of pregnane X receptor by nuclear receptor corepressor silencing mediator of retinoid and thyroid hormone receptors (SMRT). Mol. Pharmacol. 2006, 69:99-108.
11. Noble S.M., Carnahan V.E., Moore L.B., Luntz T., Wang H., Ittoop O.R., Stimmel J.B., Davis-Searles P.R., Watkins R.E., Wisely G.B., LeCluyse E., Tripathy A., McDonnell D.P., Redinbo M.R. Human PXR forms a tryptophan zipper-mediated homodimer. Biochemistry 2006, 45:8579-8589.
12. Dai G., He L., Bu P., Wan Y.J. Pregnane X receptor is essential for normal progression of liver regeneration. Hepatology 2008, 47:1277-1287.
13. Xie W., Barwick J.L., Downes M., Blumberg B., Simon C.M., Nelson M.C., Neuschwander-Tetri B.A., Brunt E.M., Guzelian P.S., Evans R.M. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 2000, 406:435-439.
14. Elcombe C.R., Elcombe B.M., Foster J.R., Chang S.C., Ehresman D.J., Butenhoff J.L. Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats from dietary exposure to potassium perfluorooctanesulfonate results from increased expression of xenosensor nuclear receptors PPARalpha and CAR/PXR. Toxicology 2012, 293:16-29.
15. Elcombe C.R., Elcombe B.M., Foster J.R., Chang S.C., Ehresman D.J., Noker P.E., Butenhoff J.L. Evaluation of hepatic and thyroid responses in male Sprague Dawley rats for up to eighty-four days following seven days of dietary exposure to potassium perfluorooctanesulfonate. Toxicology 2012, 293:30-40.
16. Elcombe C.R., Elcombe B.M., Foster J.R., Farrar D.G., Jung R., Chang S.C., Kennedy G.L., Butenhoff J.L. Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats following dietary exposure to ammonium perfluorooctanoate occurs through increased activation of the xenosensor nuclear receptors PPARalpha and CAR/PXR. Arch. Toxicol. 2010, 84:787-798.
17. Igarashi M., Yogiashi Y., Mihara M., Takada I., Kitagawa H., Kato S. Vitamin K induces osteoblast differentiation through pregnane X receptor-mediated transcriptional control of the Msx2 gene. Mol. Cell. Biol. 2007, 27:7947-7954.
18. Kameda T., Miyazawa K., Mori Y., Yuasa T., Shiokawa M., Nakamaru Y., Mano H., Hakeda Y., Kameda A., Kumegawa M. Vitamin K2 inhibits osteoclastic bone resorption by inducing osteoclast apoptosis. Biochem. Biophys. Res. Commun. 1996, 220:515-519.
19. Tabb M.M., Sun A., Zhou C., Grun F., Errandi J., Romero K., Pham H., Inoue S., Mallick S., Lin M., Forman B.M., Blumberg B. Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J. Biol. Chem. 2003, 278:43919-43927.
20. Dotzlaw H., Leygue E., Watson P., Murphy L.C. The human orphan receptor PXR messenger RNA is expressed in both normal and neoplastic breast tissue. Clin. Cancer Res. 1999, 5:2103-2107.
21. Miki Y., Suzuki T., Kitada K., Yabuki N., Shibuya R., Moriya T., Ishida T., Ohuchi N., Blumberg B., Sasano H. Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res. 2006, 66:535-542.
22. Conde I., Lobo M.V., Zamora J., Perez J., Gonzalez F.J., Alba E., Fraile B., Paniagua R., Arenas M.I. Human pregnane X receptor is expressed in breast carcinomas, potential heterodimers formation between hPXR and RXR-alpha. BMC Cancer 2008, 8:174.
23. Meyer Zu Schwabedissen H.E., Tirona R.G., Yip C.S., Ho R.H., Kim R.B. Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res. 2008, 68:9338-9347.
24. Verma S., Tabb M.M., Blumberg B. Activation of the steroid and xenobiotic receptor, SXR, induces apoptosis in breast cancer cells. BMC Cancer 2009, 9:3.
25. Chen Y., Tang Y., Wang M.T., Zeng S., Nie D. Human pregnane X receptor and resistance to chemotherapy in prostate cancer. Cancer Res. 2007, 67:10361-10367.
26. Gupta D., Venkatesh M., Wang H., Kim S., Sinz M., Goldberg G.L., Whitney K., Longley C., Mani S. Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer. Clin. Cancer Res. 2008, 14:5332-5340.
27. Yue X., Akahira J., Utsunomiya H., Miki Y., Takahashi N., Niikura H., Ito K., Sasano H., Okamura K., Yaegashi N. Steroid and Xenobiotic Receptor (SXR) as a possible prognostic marker in epithelial ovarian cancer. Pathol. Int. 2010, 60:400-406.
28. Harmsen S., Meijerman I., Febus C.L., Maas-Bakker R.F., Beijnen J.H., Schellens J.H. PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother. Pharmacol. 2010, 66:765-771.
29. Raynal C., Pascussi J.M., Leguelinel G., Breuker C., Kantar J., Lallemant B., Poujol S., Bonnans C., Joubert D., Hollande F., Lumbroso S., Brouillet J.P., Evrard A. Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol. Cancer 2010, 9:46.
30. Zhou J., Liu M., Zhai Y., Xie W. The antiapoptotic role of pregnane X receptor in human colon cancer cells. Mol. Endocrinol. 2008, 22:868-880.
31. Gong H., Singh S.V., Singh S.P., Mu Y., Lee J.H., Saini S.P., Toma D., Ren S., Kagan V.E., Day B.W., Zimniak P., Xie W. Orphan nuclear receptor pregnane X receptor sensitizes oxidative stress responses in transgenic mice and cancerous cells. Mol. Endocrinol. 2006, 20:279-290.
32. Wang H., Venkatesh M., Li H., Goetz R., Mukherjee S., Biswas A., Zhu L., Kaubisch A., Wang L., Pullman J., Whitney K., Kuro-o M., Roig A.I., Shay J.W., Mohammadi M., Mani S. Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice. J. Clin. Invest. 2011, 121:3220-3232.
33. Ouyang N., Ke S., Eagleton N., Xie Y., Chen G., Laffins B., Yao H., Zhou B., Tian Y. Pregnane X receptor suppresses proliferation and tumourigenicity of colon cancer cells. Br. J. Cancer 2010, 102:1753-1761.
34. Masuyama H., Hiramatsu Y., Kodama J., Kudo T. Expression and potential roles of pregnane X receptor in endometrial cancer. J. Clin. Endocrinol. Metab. 2003, 88:4446-4454.
35. Masuyama H., Nakatsukasa H., Takamoto N., Hiramatsu Y. Down-regulation of pregnane X receptor contributes to cell growth inhibition and apoptosis by anticancer agents in endometrial cancer cells. Mol. Pharmacol. 2007, 72:1045-1053.
36. Chen Y., Nie D. Pregnane X receptor and its potential role in drug resistance in cancer treatment. Recent Pat Anticancer Drug Discov. 2009, 4:19-27.
37. Chen Y., Tang Y., Guo C., Wang J., Boral D., Nie D. Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem. Pharmacol. 2012, 83:1112-1126.
38. Mensah-Osman E.J., Thomas D.G., Tabb M.M., Larios J.M., Hughes D.P., Giordano T.J., Lizyness M.L., Rae J.M., Blumberg B., Hollenberg P.F., Baker L.H. Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer 2007, 109:957-965.
39. Chen Y., Tang Y., Chen S., Nie D. Regulation of drug resistance by human pregnane X receptor in breast cancer. Cancer Biol. Ther. 2009, 8:1265-1272.
40. Fujimura T., Takahashi S., Urano T., Tanaka T., Zhang W., Azuma K., Takayama K., Obinata D., Murata T., Horie-Inoue K., Kodama T., Ouchi Y., Homma Y., Inoue S. Clinical significance of steroid and xenobiotic receptor and its targeted gene CYP3A4 in human prostate cancer. Cancer Sci. 2012, 103:176-180.
41. Chen T. Overcoming drug resistance by regulating nuclear receptors. Adv. Drug Deliv. Rev. 2010, 62:1257-1264.
42. Harmsen S., Meijerman I., Beijnen J.H., Schellens J.H. The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treat. Rev. 2007, 33:369-380.
43. Zucchini N., de Sousa G., Bailly-Maitre B., Gugenheim J., Bars R., Lemaire G., Rahmani R. Regulation of Bcl-2 and Bcl-xL anti-apoptotic protein expression by nuclear receptor PXR in primary cultures of human and rat hepatocytes. Biochim. Biophys. Acta 2005, 1745:48-58.
44. Acevedo R., Parnell P.G., Villanueva H., Chapman L.M., Gimenez T., Gray S.L., Baldwin W.S. The contribution of hepatic steroid metabolism to serum estradiol and estriol concentrations in nonylphenol treated MMTVneu mice and its potential effects on breast cancer incidence and latency. J. Appl. Toxicol.: JAT 2005, 25:339-353.
45. Desnoyers L.R., Pai R., Ferrando R.E., Hotzel K., Le T., Ross J., Carano R., D'Souza A., Qing J., Mohtashemi I., Ashkenazi A., French D.M. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008, 27:85-97.
46. Zheng X.E., Wang Z., Liao M.Z., Lin Y.S., Shuhart M.C., Schuetz E.G., Thummel K.E. Human PXR-mediated induction of intestinal CYP3A4 attenuates 1alpha,25-dihydroxyvitamin D(3) function in human colon adenocarcinoma LS180 cells. Biochem. Pharmacol. 2012, 84:391-401.
47. Habano W., Gamo T., Terashima J., Sugai T., Otsuka K., Wakabayashi G., Ozawa S. Involvement of promoter methylation in the regulation of Pregnane X receptor in colon cancer cells. BMC Cancer 2011, 11:81.
48. Kodama S., Negishi M. Pregnane X receptor PXR activates the GADD45beta gene, eliciting the p38 MAPK signal and cell migration. J. Biol. Chem. 2011, 286:3570-3578.
49. Rioja J., Bandres E., Rosell Costa D., Rincon A., Lopez I., Zudaire Bergera J.J., Garcia Foncillas J., Gil M.J., Panizo A., Plaza L., Rioja L.A., Berian Polo J.M. Association of steroid and xenobiotic receptor (SXR) and multidrug resistance 1 (MDR1) gene expression with survival among patients with invasive bladder carcinoma. BJU International 2011, 107:1833-1838.
50. Rioja Zuazu J., Bandres Elizalde E., Rosell Costa D., Rincon Mayans A., Zudaire Bergera J., Gil Sanz M.J., Rioja Sanz L.A., Garcia Foncillas J., Berian Polo J.M. Steroid and xenobiotic receptor (SXR), multidrug resistance gene (MDR1) and GSTs, SULTs and CYP polymorphism expression in invasive bladder cancer, analysis of their expression and correlation with other prognostic factors. Actas Urol. Esp. 2007, 31:1107-1116.
51. van de Winkel A., van Zoest K.P., van Dekken H., Moons L.M., Kuipers E.J., van der Laan L.J. Differential expression of the nuclear receptors farnesoid X receptor (FXR) and pregnane X receptor (PXR) for grading dysplasia in patients with Barrett's oesophagus. Histopathology 2011, 58:246-253.
52. Takeyama D., Miki Y., Fujishima F., Suzuki T., Akahira J., Hata S., Miyata G., Satomi S., Sasano H. Steroid and xenobiotic receptor in human esophageal squamous cell carcinoma: a potent prognostic factor. Cancer Sci. 2010, 101:543-549.
53. Kuriki K., Hamajima N., Chiba H., Kanemitsu Y., Hirai T., Kato T., Saito T., Matsuo K., Koike K., Tokudome S., Tajima K. Increased risk of colorectal cancer due to interactions between meat consumption and the CD36 gene A52C polymorphism among Japanese. Nutr. Cancer 2005, 51:170-177.
54. Moya M., Gomez-Lechon M.J., Castell J.V., Jover R. Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. Chem. Biol. Interact. 2010, 184:376-387.
55. Zhan Y., Ginanni N., Tota M.R., Wu M., Bays N.W., Richon V.M., Kohl N.E., Bachman E.S., Strack P.R., Krauss S. Control of cell growth and survival by enzymes of the fatty acid synthesis pathway in HCT-116 colon cancer cells. Clin. Cancer Res. 2008, 14:5735-5742.
56. Azuma K., Urano T., Watabe T., Ouchi Y., Inoue S. PROX1 suppresses vitamin K-induced transcriptional activity of Steroid and Xenobiotic Receptor. Genes to Cells: Devoted Mol. Cell. Mech. 2011, 16:1063-1070.
57. Takagi S., Nakajima M., Mohri T., Yokoi T. Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J. Biol. Chem. 2008, 283:9674-9680.
58. Misawa A., Inoue J., Sugino Y., Hosoi H., Sugimoto T., Hosoda F., Ohki M., Imoto I., Inazawa J. Methylation-associated silencing of the nuclear receptor 1I2 gene in advanced-type neuroblastomas, identified by bacterial artificial chromosome array-based methylated CpG island amplification. Cancer Res. 2005, 65:10233-10242.
59. Xie Y., Ke S., Ouyang N., He J., Xie W., Bedford M.T., Tian Y. Epigenetic regulation of transcriptional activity of pregnane X receptor by protein arginine methyltransferase 1. J. Biol. Chem. 2009, 284:9199-9205.
60. Zhai Y., Pai H.V., Zhou J., Amico J.A., Vollmer R.R., Xie W. Activation of pregnane X receptor disrupts glucocorticoid and mineralocorticoid homeostasis. Mol. Endocrinol. 2007, 21:138-147.
61. Zhang B., Cheng Q., Ou Z., Lee J.H., Xu M., Kochhar U., Ren S., Huang M., Pflug B.R., Xie W. Pregnane X receptor as a therapeutic target to inhibit androgen activity. Endocrinology 2010, 151:5721-5729.
62. Chaturvedi N.K., Kumar S., Negi S., Tyagi R.K. Endocrine disruptors provoke differential modulatory responses on androgen receptor and pregnane and xenobiotic receptor: potential implications in metabolic disorders. Mol. Cell. Biochem. 2010, 345:291-308.
63. Kumar S., Jaiswal B., Negi S., Tyagi R.K. Cross-talk between androgen receptor and pregnane and xenobiotic receptor reveals existence of a novel modulatory action of anti-androgenic drugs. Biochem. Pharmacol. 2010, 80:964-976.
64. Casabar R.C., Das P.C., Dekrey G.K., Gardiner C.S., Cao Y., Rose R.L., Wallace A.D. Endosulfan induces CYP2B6 and CYP3A4 by activating the pregnane X receptor. Toxicol. Appl. Pharmacol. 2010, 245:335-343.
65. Cooper B.W., Cho T.M., Thompson P.M., Wallace A.D. Phthalate induction of CYP3A4 is dependent on glucocorticoid regulation of PXR expression. Toxicol. Sci. 2008, 103:268-277.
66. Coumoul X., Diry M., Barouki R. PXR-dependent induction of human CYP3A4 gene expression by organochlorine pesticides. Biochem. Pharmacol. 2002, 64:1513-1519.
67. DeKeyser J.G., Laurenzana E.M., Peterson E.C., Chen T., Omiecinski C.J. Selective phthalate activation of naturally occurring human constitutive androstane receptor splice variants and the pregnane X receptor. Toxicol. Sci. 2011, 120:381-391.
68. Hurst C.H., Waxman D.J. Environmental phthalate monoesters activate pregnane X receptor-mediated transcription. Toxicol. Appl. Pharmacol. 2004, 199:266-274.
69. Jacobs M.N., Nolan G.T., Hood S.R. Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol. Appl. Pharmacol. 2005, 209:123-133.
70. Kojima H., Sata F., Takeuchi S., Sueyoshi T., Nagai T. Comparative study of human and mouse pregnane X receptor agonistic activity in 200 pesticides using in vitro reporter gene assays. Toxicology 2011, 280:77-87.
71. Kretschmer X.C., Baldwin W.S. CAR and PXR: xenosensors of endocrine disrupters?. Chem. Biol. Interact. 2005, 155:111-128.
72. Lemaire G., Mnif W., Pascussi J.M., Pillon A., Rabenoelina F., Fenet H., Gomez E., Casellas C., Nicolas J.C., Cavailles V., Duchesne M.J., Balaguer P. Identification of new human pregnane X receptor ligands among pesticides using a stable reporter cell system. Toxicol. Sci. 2006, 91:501-509.
73. Masuyama H., Hiramatsu Y., Kunitomi M., Kudo T., MacDonald P.N. Endocrine disrupting chemicals, phthalic acid and nonylphenol, activate Pregnane X receptor-mediated transcription. Mol. Endocrinol. 2000, 14:421-428.
74. Medina-Diaz I.M., Arteaga-Illan G., de Leon M.B., Cisneros B., Sierra-Santoyo A., Vega L., Gonzalez F.J., Elizondo G. Pregnane X receptor-dependent induction of the CYP3A4 gene by o, p'-1,1,1,-trichloro-2,2-bis (p-chlorophenyl)ethane. Drug Metab. Dispos. 2007, 35:95-102.
75. Mikamo E., Harada S., Nishikawa J., Nishihara T. Endocrine disruptors induce cytochrome P450 by affecting transcriptional regulation via pregnane X receptor. Toxicol. Appl. Pharmacol. 2003, 193:66-72.
76. Mnif W., Pascussi J.M., Pillon A., Escande A., Bartegi A., Nicolas J.C., Cavailles V., Duchesne M.J., Balaguer P. Estrogens and antiestrogens activate hPXR. Toxicol. Lett. 2007, 170:19-29.
77. Takeshita A., Koibuchi N., Oka J., Taguchi M., Shishiba Y., Ozawa Y. Bisphenol-A, an environmental estrogen, activates the human orphan nuclear receptor, steroid and xenobiotic receptor-mediated transcription. Eur. J. Endocrinol./European Federation of Endocrine Societies 2001, 145:513-517.
78. Wyde M.E., Bartolucci E., Ueda A., Zhang H., Yan B., Negishi M., You L. The environmental pollutant 1,1-dichloro-2,2-bis (p-chlorophenyl)ethylene induces rat hepatic cytochrome P450 2B and 3A expression through the constitutive androstane receptor and pregnane X receptor. Mol. Pharmacol. 2003, 64:474-481.
79. Wyde M.E., Kirwan S.E., Zhang F., Laughter A., Hoffman H.B., Bartolucci-Page E., Gaido K.W., Yan B., You L. Di-n-butyl phthalate activates constitutive androstane receptor and pregnane X receptor and enhances the expression of steroid-metabolizing enzymes in the liver of rat fetuses. Toxicol. Sci. 2005, 86:281-290.
80. Yang D., Wang X., Chen Y.T., Deng R., Yan B. Pyrethroid insecticides: isoform-dependent hydrolysis, induction of cytochrome P450 3A4 and evidence on the involvement of the pregnane X receptor. Toxicol. Appl. Pharmacol. 2009, 237:49-58.
81. Dairkee S.H., Seok J., Champion S., Sayeed A., Mindrinos M., Xiao W., Davis R.W., Goodson W.H. Bisphenol A induces a profile of tumor aggressiveness in high-risk cells from breast cancer patients. Cancer Res. 2008, 68:2076-2080.
82. Diamanti-Kandarakis E., Bourguignon J.P., Giudice L.C., Hauser R., Prins G.S., Soto A.M., Zoeller R.T., Gore A.C. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr. Rev. 2009, 30:293-342.
83. LaPensee E.W., Ben-Jonathan N. Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy. Endocr. Relat. Cancer 2010, 17:R91-107.
84. LaPensee E.W., LaPensee C.R., Fox S., Schwemberger S., Afton S., Ben-Jonathan N. Bisphenol A and estradiol are equipotent in antagonizing cisplatin-induced cytotoxicity in breast cancer cells. Cancer Lett. 2010, 290:167-173.
85. Takeshita A., Inagaki K., Igarashi-Migitaka J., Ozawa Y., Koibuchi N. The endocrine disrupting chemical, diethylhexyl phthalate, activates MDR1 gene expression in human colon cancer LS174T cells. J. Endocrinol. 2006, 190:897-902.
86. Xu X., Dailey A.B., Talbott E.O., Ilacqua V.A., Kearney G., Asal N.R. Associations of serum concentrations of organochlorine pesticides with breast cancer and prostate cancer in U.S. adults. Environ. Health Perspect. 2010, 118:60-66.
87. Zhu H., Zheng J., Xiao X., Zheng S., Dong K., Liu J., Wang Y. Environmental endocrine disruptors promote invasion and metastasis of SK-N-SH human neuroblastoma cells. Oncol. Rep. 2010, 23:129-139.
88. Soto A.M., Sonnenschein C. Environmental causes of cancer: endocrine disruptors as carcinogens. Nat. Rev. Endocrinol. 2010, 6:363-370.
89. Lichti-Kaiser K., Xu C., Staudinger J.L. Cyclic AMP-dependent protein kinase signaling modulates pregnane X receptor activity in a species-specific manner. J. Biol. Chem. 2009, 284:6639-6649.
90. Pondugula S.R., Dong H., Chen T. Phosphorylation and protein-protein interactions in PXR-mediated CYP3A repression. Exp. Opin. Drug Metab. Toxicol. 2009, 5:861-873.
91. Ma X., Shah Y., Cheung C., Guo G.L., Feigenbaum L., Krausz K.W., Idle J.R., Gonzalez F.J. The PREgnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A. Drug Metab. Dispos. 2007, 35:194-200.
92. Moore L.B., Maglich J.M., McKee D.D., Wisely B., Willson T.M., Kliewer S.A., Lambert M.H., Moore J.T. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol. Endocrinol. 2002, 16:977-986.
93. Gordon I., Paoloni M., Mazcko C., Khanna C. The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med. 2009, 6:e1000161.
94. Khanna C., Lindblad-Toh K., Vail D., London C., Bergman P., Barber L., Breen M., Kitchell B., McNeil E., Modiano J.F., Niemi S., Comstock K.E., Ostrander E., Westmoreland S., Withrow S. The dog as a cancer model. Nat. Biotechnol. 2006, 24:1065-1066.
95. Ao A., Wang H., Kamarajugadda S., Lu J. Involvement of estrogen-related receptors in transcriptional response to hypoxia and growth of solid tumors. Proc. Nat. Acad. Sci. USA 2008, 105:7821-7826.
96. Stein R.A., Chang C.Y., Kazmin D.A., Way J., Schroeder T., Wergin M., Dewhirst M.W., McDonnell D.P. Estrogen-related receptor alpha is critical for the growth of estrogen receptor-negative breast cancer. Cancer Res. 2008, 68:8805-8812.
97. Birrell M.A., De Alba J., Catley M.C., Hardaker E., Wong S., Collins M., Clarke D.L., Farrow S.N., Willson T.M., Collins J.L., Belvisi M.G. Liver X receptor agonists increase airway reactivity in a model of asthma via increasing airway smooth muscle growth. J. Immunol. 2008, 181:4265-4271.
98. Garcia-Aragoncillo E., Carrillo J., Lalli E., Agra N., Gomez-Lopez G., Pestana A., Alonso J. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells. Oncogene 2008, 27:6034-6043.
99. Martinez-Gonzalez J., Rius J., Castello A., Cases-Langhoff C., Badimon L. Neuron-derived orphan receptor-1 (NOR-1) modulates vascular smooth muscle cell proliferation. Circ. Res. 2003, 92:96-103.
100. Baskin-Bey E.S., Huang W., Ishimura N., Isomoto H., Bronk S.F., Braley K., Craig R.W., Moore D.D., Gores G.J. Constitutive androstane receptor (CAR) ligand, TCPOBOP, attenuates Fas-induced murine liver injury by altering Bcl-2 proteins. Hepatology 2006, 44:252-262.
101. Huang W., Zhang J., Washington M., Liu J., Parant J.M., Lozano G., Moore D.D. Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol. Endocrinol. 2005, 19:1646-1653.
102. Oliver J.D., Roberts R.A. Receptor-mediated hepatocarcinogenesis: role of hepatocyte proliferation and apoptosis. Pharmacol. Toxicol. 2002, 91:1-7.
103. Yamamoto Y., Negishi M. The antiapoptotic factor growth arrest and DNA-damage-inducible 45 beta regulates the nuclear receptor constitutive active/androstane receptor-mediated transcription. Drug Metab. Dispos. 2008, 36:1189-1193.
104. Chen Y.L., Jian M.H., Lin C.C., Kang J.C., Chen S.P., Lin P.C., Hung P.J., Chen J.R., Chang W.L., Lin S.Z., Harn H.J. The induction of orphan nuclear receptor Nur77 expression by n-butylenephthalide as pharmaceuticals on hepatocellular carcinoma cell therapy. Mol. Pharmacol. 2008, 74:1046-1058.
105. Kolluri S.K., Zhu X., Zhou X., Lin B., Chen Y., Sun K., Tian X., Town J., Cao X., Lin F., Zhai D., Kitada S., Luciano F., O'Donnell E., Cao Y., He F., Lin J., Reed J.C., Satterthwait A.C., Zhang X.K. A short Nur77-derived peptide converts Bcl-2 from a protector to a killer. Cancer Cell 2008, 14:285-298.
106. Botrugno O.A., Fayard E., Annicotte J.S., Haby C., Brennan T., Wendling O., Tanaka T., Kodama T., Thomas W., Auwerx J., Schoonjans K. Synergy between LRH-1 and beta-catenin induces G1 cyclin-mediated cell proliferation. Mol. Cell 2004, 15:499-509.
107. He N., Park K., Zhang Y., Huang J., Lu S., Wang L. Epigenetic inhibition of nuclear receptor small heterodimer partner is associated with and regulates hepatocellular carcinoma growth. Gastroenterology 2008, 134:793-802.
108. Chearwae W., Bright J.J. PPARgamma agonists inhibit growth and expansion of CD133+ brain tumour stem cells. Br. J. Cancer 2008, 99:2044-2053.
109. Elrod H.A., Sun S.Y. PPARgamma and apoptosis in cancer. PPAR Res. 2008, 2008:704165.
110. Garcia-Bates T.M., Bernstein S.H., Phipps R.P. Peroxisome proliferator-activated receptor gamma overexpression suppresses growth and induces apoptosis in human multiple myeloma cells. Clin. Cancer Res. 2008, 14:6414-6425.
111. Nagata D., Yoshihiro H., Nakanishi M., Naruyama H., Okada S., Ando R., Tozawa K., Kohri K. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer. Cancer Detect. Prev. 2008, 32:259-266.
112. Swales K.E., Korbonits M., Carpenter R., Walsh D.T., Warner T.D., Bishop-Bailey D. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res. 2006, 66:10120-10126.
113. Yu S., Wong Y.C., Wang X.H., Ling M.T., Ng C.F., Chen S., Chan F.L. Orphan nuclear receptor estrogen-related receptor-beta suppresses in vitro and in vivo growth of prostate cancer cells via p21(WAF1/CIP1) induction and as a potential therapeutic target in prostate cancer. Oncogene 2008, 27:3313-3328.
114. Yu S., Wang X., Ng C.F., Chen S., Chan F.L. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer. Cancer Res. 2007, 67:4904-4914.
115. Gong H., Guo P., Zhai Y., Zhou J., Uppal H., Jarzynka M.J., Song W.C., Cheng S.Y., Xie W. Estrogen deprivation and inhibition of breast cancer growth in vivo through activation of the orphan nuclear receptor liver X receptor. Mol. Endocrinol. 2007, 21:1781-1790.
116. Kolluri S.K., Bruey-Sedano N., Cao X., Lin B., Lin F., Han Y.H., Dawson M.I., Zhang X.K. Mitogenic effect of orphan receptor TR3 and its regulation by MEKK1 in lung cancer cells. Mol. Cell. Biol. 2003, 23:8651-8667.
117. Mu X., Chang C. TR3 orphan nuclear receptor mediates apoptosis through up-regulating E2F1 in human prostate cancer LNCaP cells. J. Biol. Chem. 2003, 278:42840-42845.
118. Zeng L., Geng Y., Tretiakova M., Yu X., Sicinski P., Kroll T.G. Peroxisome proliferator-activated receptor-delta induces cell proliferation by a cyclin E1-dependent mechanism and is up-regulated in thyroid tumors. Cancer Res. 2008, 68:6578-6586.
119. Borland M.G., Foreman J.E., Girroir E.E., Zolfaghari R., Sharma A.K., Amin S., Gonzalez F.J., Ross A.C., Peters J.M. Ligand activation of peroxisome proliferator-activated receptor-beta/delta inhibits cell proliferation in human HaCaT keratinocytes. Mol. Pharmacol. 2008, 74:1429-1442.
120. Lamba V., Yasuda K., Lamba J.K., Assem M., Davila J., Strom S., Schuetz E.G. PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol. Appl. Pharmacol. 2004, 199:251-265.
121. Gardner-Stephen D., Heydel J.M., Goyal A., Lu Y., Xie W., Lindblom T., Mackenzie P., Radominska-Pandya A. Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression. Drug Metab. Dispos. 2004, 32:340-347.
122. Tompkins L.M., Sit T.L., Wallace A.D. Unique transcription start sites and distinct promoter regions differentiate the pregnane X receptor (PXR) isoforms PXR 1 and PXR 2. Drug Metab. Dispos. 2008, 36:923-929.
123. Lin Y.S., Yasuda K., Assem M., Cline C., Barber J., Li C.W., Kholodovych V., Ai N., Chen J.D., Welsh W.J., Ekins S., Schuetz E.G. The major human pregnane X receptor (PXR) splice variant, PXR.2, exhibits significantly diminished ligand-activated transcriptional regulation. Drug Metab. Dispos. 2009, 37:1295-1304.
124. Naor D., Nedvetzki S., Golan I., Melnik L., Faitelson Y. CD44 in cancer. Crit. Rev. Clin. Lab. Sci. 2002, 39:527-579.
125. Matic M., Corradin A.P., Tsoli M., Clarke S.J., Polly P., Robertson G.R. The alternatively spliced murine pregnane X receptor isoform, mPXR(delta171-211) exhibits a repressive action. Int. J. Biochem. Cell Biol. 2010, 42:672-682.
126. Biswas A., Pasquel D., Tyagi R.K., Mani S. Acetylation of pregnane X receptor protein determines selective function independent of ligand activation. Biochem. Biophys. Res. Commun. 2011, 406:371-376.
127. Pondugula S.R., Brimer-Cline C., Wu J., Schuetz E.G., Tyagi R.K., Chen T. A phosphomimetic mutation at threonine-57 abolishes transactivation activity and alters nuclear localization pattern of human pregnane x receptor. Drug Metab. Dispos. 2009, 37:719-730.
128. Staudinger J.L., Xu C., Biswas A., Mani S. Post-translational modification of pregnane x receptor. Pharmacol. Res.: Off. J. Ital. Pharmacol. Soc. 2011, 64:4-10.
129. Gramatzki D., Pantazis G., Schittenhelm J., Tabatabai G., Kohle C., Wick W., Schwarz M., Weller M., Tritschler I. Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells. Oncogene 2009, 28:2593-2605.
130. Opitz C.A., Litzenburger U.M., Sahm F., Ott M., Tritschler I., Trump S., Schumacher T., Jestaedt L., Schrenk D., Weller M., Jugold M., Guillemin G.J., Miller C.L., Lutz C., Radlwimmer B., Lehmann I., von Deimling A., Wick W., Platten M. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011, 478:197-203.
131. Rhodes J.M., Campbell B.J. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol. Med. 2002, 8:10-16.
132. Viennot S., Deleporte A., Moussata D., Nancey S., Flourie B., Reimund J.M. Colon cancer in inflammatory bowel disease: recent trends, questions and answers. Gastroenterol. Clin. Biol. 2009, 33(Suppl. 3):S190-201.
133. Gao M., Guo N., Huang C., Song L. Diverse roles of GADD45alpha in stress signaling. Curr. Protein Pept. Sci. 2009, 10:388-394.
134. Prochownik E.V. C-Myc: linking transformation and genomic instability. Curr. Mol. Med. 2008, 8:446-458.
135. Zhang Y., Chen L., Yang S., Fang D. E2F1: a potential negative regulator of hTERT transcription in normal cells upon activation of oncogenic c-Myc. Med. Sci. Monit.: Int. Med. J. Exp. Clin. Res. 2012, 18:RA12-RA15.
136. Bluemn E.G., Nelson P.S. The androgen/androgen receptor axis in prostate cancer. Curr. Opin. Oncol. 2012, 24:251-257.
137. Lebovitz C.B., Bortnik S.B., Gorski S.M. Here, there be dragons: charting autophagy-related alterations in human tumors. Clin. Cancer Res. 2012, 18:1214-1226.
138. Reimann M., Schmitt C.A., Lee S. Non-cell-autonomous tumor suppression: oncogene-provoked apoptosis promotes tumor cell senescence via stromal crosstalk. J. Mol. Med. (Berl.) 2011, 89:869-875.
139. Saab R. Senescence and pre-malignancy: how do tumors progress?. Semin. Cancer Biol. 2011, 21:385-391.
140. Wang Y.M., Ong S.S., Chai S.C., Chen T. Role of CAR and PXR in xenobiotic sensing and metabolism. Exp. Opin. Drug Metab. Toxicol. 2012, 8:803-817.
141. Bowlby S.C., Thomas M.J., D'Agostino R.B., Kridel S.J. Nicotinamide phosphoribosyl transferase (nampt) is required for de novo lipogenesis in tumor cells. PLoS ONE 2012, 7:e40195.
142. Rysman E., Brusselmans K., Scheys K., Timmermans L., Derua R., Munck S., Van Veldhoven P.P., Waltregny D., Daniels V.W., Machiels J., Vanderhoydonc F., Smans K., Waelkens E., Verhoeven G., Swinnen J.V. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 2010, 70:8117-8126.
143. Swinnen J.V., Brusselmans K., Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr. Opin. Clin. Nutr. Metab. Care 2006, 9:358-365.
144. A.P. Hall, C.R. Elcombe, J.R. Foster, T. Harada, W. Kaufmann, A. Knipple, K. Kutttler, D.E. Malarkey, R.R. Maronpot, A. Nishikawa, T. Nolte, A. Schulte, V. Strauss, M.J. York, Liver Hypertrophy: A Review of Adaptive (Adverse and Non-adverse) Changes-Conclusions from the 3rd International ESTP Expert Workshop. Toxicol. Pathol., 2012.
145. van de Winkel A., Menke V., Capello A., Moons L.M., Pot R.G., van Dekken H., Siersema P.D., Kusters J.G., van der Laan L.J., Kuipers E.J. Expression, localization and polymorphisms of the nuclear receptor PXR in Barrett's esophagus and esophageal adenocarcinoma. BMC Gastroenterol. 2011, 11:108.
146. Zhuang W., Jia Z., Feng H., Chen J., Wang H., Guo Y., Meng C. The mechanism of the G0/G1 cell cycle phase arrest induced by activation of PXR in human cells. Biomed. Pharmacother = Biomedecine & pharmacotherapie 2011, 65:467-473.
147. Chen T. Nuclear receptor drug discovery. Curr. Opin. Chem. Biol. 2008, 12:418-426.
148. Chen Y., Tang Y., Robbins G.T., Nie D. Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor. J. Pharmacol. Exp. Ther. 2010, 334:999-1008.
149. Healan-Greenberg C., Waring J.F., Kempf D.J., Blomme E.A., Tirona R.G., Kim R.B. A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. Drug Metab. Dispos. 2008, 36:500-507.
150. Huang H., Wang H., Sinz M., Zoeckler M., Staudinger J., Redinbo M.R., Teotico D.G., Locker J., Kalpana G.V., Mani S. Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 2007, 26:258-268.
151. Venkatesh M., Wang H., Cayer J., Leroux M., Salvail D., Das B., Wrobel J.E., Mani S. In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation. Mol. Pharmacol. 2011, 80:124-135.
152. Wang H., Huang H., Li H., Teotico D.G., Sinz M., Baker S.D., Staudinger J., Kalpana G., Redinbo M.R., Mani S. Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin. Cancer Res. 2007, 13:2488-2495.
153. Wang H., Li H., Moore L.B., Johnson M.D., Maglich J.M., Goodwin B., Ittoop O.R., Wisely B., Creech K., Parks D.J., Collins J.L., Willson T.M., Kalpana G.V., Venkatesh M., Xie W., Cho S.Y., Roboz J., Redinbo M., Moore J.T., Mani S. The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. Mol. Endocrinol. 2008, 22:838-857.
154. Zhou C., Poulton E.J., Grun F., Bammler T.K., Blumberg B., Thummel K.E., Eaton D.L. The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol. Pharmacol. 2007, 71:220-229.